p21 as a prognostic factor in non-small cell lung carcinomas

Pathology Research and Practice

Volumn 202, Issue 12, 2006, Pages 849-856

  Kwon, Mi Seon ^a   Lee, Young Il ^a   Lee, Kyo Young ^b  

^a Dankook University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Non small cell lung carcinoma; p21; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P21;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UNIVARIATE ANALYSIS;

EID: 33751014828     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2006.08.004     Document Type: Article

References (43)

1. Bearss D.J., Lee R.J., Troyer D.A., Pestell R.G., and Windle J.J. Differential effects of p21/WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res. 62 (2002) 2077-2084
2. Bennett W.P., el-Deiry W.S., Rush W.L., Guinee Jr. D.G., Freedman A.N., Caporaso N.E., Welsh J.A., Jones R.T., Borkowski A., Travis W.D., Fleming M.V., Trastek V., Pairolero P.C., Tazelaar H.D., Midthun D., Jett J.R., Liotta L.A., and Harris C.C. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin. Cancer Res. 4 (1998) 1499-1506
3. Brown J.P., Wei W., and Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277 (1997) 831-834
4. Caffo O., Doglioni C., Veronese S., Bonzanini M., Marchetti A., Buttitta F., Fina P., Leek R., Morelli L., Palma P.D., Harris A.L., and Barbareschi M. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 2 (1996) 1591-1599
5. Caputi M., Esposito V., Baldi A., De Luca A., Dean C., Signoriello G., Baldi F., and Giordano A. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am. J. Respir. Cell Mol. Biol. 18 (1998) 213-217
6. Chang B.-D., Watanabe K., Broude E.V., Fang J., Poole J.C., Kalinichenko T.V., and Roninson I. Effects of p21/Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. USA 97 (2000) 4291-4296
7. Costa M.J., Hansen C.L., Walls J.E., and Scudder S.A. Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Hum. Pathol. 30 (1999) 640-647
8. Dergham S.T., Dugan M.C., Joshi U.S., Chen Y.C., Du W., Smith D.W., Arlauskas P., Crissman J.D., Vaitkevicius V.K., and Sarkar F.H. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Cancer 80 (1997) 372-381
9. Doglioni C., Pelosio P., Laurino L., Macri E., Meggiolaro E., Favretti F., and Barbareschi M. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J. Pathol. 179 (1996) 248-253
10. Dosaka H., Harada M., Kuzumaki N., Kobayashi H., Miyamoto H., and Kawakami Y. The relationship of clinical classification to ras p21 expression in human non-small cell lung cancer. Oncology 45 (1988) 396-400
11. Dworakowska D., Jassem E., Jassem J., Boltze C., Wiedorn K.H., Dworakowski R., Skokowski J., Jaskiewicz K., and Czestochowska E. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. Acta Oncol. 44 (2005) 75-79
12. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., and Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54 (1994) 1169-1174
13. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
14. Esposito V., Baldi A., Tonini G., Vincenzi B., Santini M., Ambrogi V., Mineo T.C., Persichetti P., Liuzzi G., Montesarchio V., Wolner E., Baldi F., and Groeger A.M. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J. Clin. Pathol. 57 (2004) 58-63
15. Fujino M., Dosaka-Akita H., Harada M., Hiroumi H., Kinoshita I., Akie K., and Kawakami Y. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 76 (1995) 2457-2463
16. Garcia del Muro X., Condom E., Vigues F., Castellsague X., Figueras A., Munoz J., Sola J., Soler T., Capella G., and Germa J.R. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100 (2004) 1859-1867
17. Goan Y.G., Hsu H.K., Chang H.C., Chou Y.P., Chiang K.H., and Cheng J.T. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann. Thorac. Surg. 80 (2005) 1007-1016
18. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., Kaibara N., and Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79 (1997) 2067-2072
19. Groeger A.M., Caputi M., Esposito V., Baldi A., Rossiello R., Santini D., Mancini A., Kaiser H.E., and Baldi F. Expression of p21 in non small cell lung cancer relationship with PCNA. Anticancer Res. 20 (2000) 3301-3305
20. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
21. Hayashi H., Miyamoto H., Ito T., Kameda Y., Nakamura N., Kubota Y., and Kitamura H. Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am. J. Pathol. 151 (1997) 461-470
22. Holland T.A., Elder J., McCloud J.M., Hall C., Deakin M., Fryer A.A., Elder J.B., and Hoban P.R. Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patient survival. Int. J. Cancer 95 (2001) 302-306
23. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., and Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9 (1994) 3397-3406
24. Johnson M., Dimitrov D., Vojta P.J., Barrett J.C., Noda A., Pereira-Smith O.M., and Smith J.R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol. Carcinogen. 11 (1994) 59-64
25. Komiya T., Hosono Y., Hirashima T., Masuda N., Yasumitsu T., Nakagawa K., Kikui M., Ohno A., Fukuoka M., and Kawase I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res. 3 (1997) 1831-1835
26. Kumar V., Abbas A.K., and Fausto N. Robbins and Cotran Pathologic Basis of Disease. seventh ed (2005), Elsevier Saunders, Philadelphia
27. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., and Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9 (1995) 935-944
28. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C.A., Dalla Palma P., and Bevilacqua G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12 (1996) 1319-1324
29. McDonald J.W., and Pilgram T.K. Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology 34 (1999) 439-446
30. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E., and Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54 (1994) 3391-3395
31. Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., and Smith J.R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211 (1994) 90-98
32. Pellikainen M.J., Pekola T.T., Ropponen K.M., Kataja V.V., Kellokoski J.K., Eskelinen M.J., and Kosma V.M. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J. Clin. Pathol. 56 (2003) 214-220
33. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179 (2002) 1-14
34. Rusin M., Butkiewicz D., Malusecka E., Zborek A., Harasim J., Czyzewski K., Bennett W.P., Shields P.G., Weston A., Welsh J.A., Krzyzowska-Gruca S., Chorazy M., and Harris C.C. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. Br. J. Cancer 80 (1999) 1445-1452
35. Sarkar F.H., Li Y., Sakr W.A., Grignon D.J., Madan S.S., Wood Jr D.P., and Adsay V. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 40 (1999) 256-260
36. Shoji T., Tanaka F., Takata T., Yanagihara K., Otake Y., Hanaoka N., Miyahara R., Nakagawa T., Kawano Y., Ishikawa S., Katakura H., and Wada H. Clinical significance of p21 expression in non-small-cell lung cancer. J. Clin. Oncol. 20 (2002) 3865-3871
37. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., and Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 11 (2005) 3974-3986
38. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., and el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9 (1994) 3389-3396
39. Takeshima Y., Yamasaki M., Nishisaka T., Kitaguchi S., and Inai K. p21WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities. Carcinogenesis 19 (1998) 1755-1761
40. Travis W.D., Brambilla E., Muller-Hermelink H.K., and Harris C.C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (2004), IARC Press, Lyon
41. Vonlanthen S., Heighway J., Kappeler A., Altermatt H.J., Borner M.M., and Betticher D.C. p21 is associated with cyclin D1, p16INK4a and pRb expression in respectable non-small cell lung cancer. Int. J. Oncol. 16 (2000) 951-957
42. Wu Q., Kirschmeier P., Hockenberry T., Yang T.Y., Brassard D.L., Wang L., McClanahan T., Black S., Rizzi G., Musco M.L., Mirza A., and Liu S. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J. Biol. Chem. 277 (2002) 36329-36337
43. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704